IBA continues to shape the future of proton therapy at ESTRO 2022 Annual Congress
06 Mai 2022 - 07:00AM
IBA continues to shape the future of proton therapy at ESTRO 2022
Annual Congress
IBA to share latest updates from its Proteus®
portfolio and the Campus community platform
Louvain-la-Neuve, Belgium, 6 May
2022 - IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology and the leading
provider of proton therapy solutions, is excited to share its
latest proton therapy insights during the Annual Congress and
exhibition of the European Society for Radiotherapy & Oncology
(ESTRO) being held in Copenhagen (Denmark) from 6-10 May, 2022.
Together with its customers, IBA is leading
proton therapy by developing state of the art treatment and
dosimetry solutions for optimal patient care.
Firstly, the Proteus® technology is designed by
users for users with four objectives in mind:
- Clinical Confidence: Designed for clinical excellence and the
most advanced patient care, Proteus® is a versatile proton therapy
system which allows oncology centers to treat a broad range of
tumors safely and effectively.
- Superior patient workflow: Proteus® is inspired by everyday
clinical practice. The Proteus® design enhances the patient
experience by fostering a relaxing environment whilst making the
medical staff’s daily practice safe and easy.
- Shaping the future of proton therapy: IBA’s product roadmap
aims at shaping the future of proton therapy, intending to augment
the potential of proton therapy in terms of therapeutic gain, ease
of use, and/or benefit-cost ratio. IBA continues its commitment to
developing clinically relevant innovations designed to improve
patient treatment in partnership with its users.
- Business excellence: With 35 years’ experience, IBA is the
world leader in its field. It boasts the largest number of
operating sites, rooms and field teams in the industry, as well as
robust and updated processes.
Additionally, IBA is proud to demonstrate its
Campus platform for the first time at ESTRO. First launched in
October 2021 and representing the largest community of proton
therapy experts, Campus has been built in collaboration with IBA’s
clinical and industry partners. It is a unique place where the
whole proton therapy community can discuss, collaborate, and share
insights with each other, as well as receive training.
Campus is a community platform built on three
principles:
- Learn: Expand your skills
- Share: Collaborate with your peers
- Excel: Maximize your center’s performance
Olivier Legrain, Chief Executive Officer
of IBA commented: “We are very happy to reconnect face to
face with our customers at ESTRO’s annual congress. We aim to
provide access to better and faster treatments for a wider set of
indications to our customers, which will in turn provide more
patients with access to proton therapy and improve their quality of
life.”
*** Ends ***About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,600 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
For further information, please
contact:
IBA
Aymeric HarmantGlobal Marketing
Director+32 10 203 796global.marketing@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
- 220504_IBA-at-ESTRO2022-EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024